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Abstract
Background: It has been suggested that combined effect of natural products may improve the treatment
effectiveness in combating proliferation of cancer cells. The present study was undertaken to evaluate the
possibility that the combination of xanthorrhizol and curcumin might show synergistic growth inhibitory
effect towards MDA-MB-231 human breast cancer cells via apoptosis induction. The effective dose that
produced 50% growth inhibition (GI50) was calculated from the log dose-response curve of fixed-
combinations of xanthorrhizol and curcumin generated from the sulforhodamine B (SRB) assay. The
experimental GI50 value was used to determine the synergistic activity of the combination treatment by
isobolographic analysis and combination-index method. Further investigation of mode of cell death induced
by the combination treatment was conducted in the present study.
Results: Isobole analysis revealed that substances interaction was synergistic when xanthorrhizol and
curcumin were added concurrently to the cultures but merely additive when they were added sequentially.
The synergistic combination treatment was then applied to the cultures to investigate the mode of cell
death induced by the treatment. Immunofluorescence staining using antibody MitoCapture™ revealed the
possibility of altered mitochondrial transmembrane potential, which is one of the hallmark of apoptosis.
Hoechst 33258 nuclear staining assay showed the rate of apoptosis of MDA-MB-231 cells to increase in
response to the treatment. Apoptotic cell death was further confirmed by DNA fragmentation assay,
where internucleosomal excision of DNA was induced upon treatment with xanthorrhizol-curcumin.
Conclusion: This is the first time the combined cytotoxic effect of xanthorrhizol and curcumin on MDA-
MB-231 cells has been documented and our findings provide experimental support to the hypothesis that
combined xanthorrhizol-curcumin showed synergistic growth inhibitory activity on MDA-MB-231 cells via
apoptosis induction.
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Background
Drug discovery from medicinal plants continues to pro-
vide an important source of new drug leads [1]. Previous
studies have reported the ability of xanthorrhizol and cur-
cumin in killing various cancer cell lines [2-7]. Our previ-
ous report on the cytotoxicity of xanthorrhizol on human
breast carcinoma MCF-7 has proved that xanthorrhizol
was able to induced apoptotic cell death [3]. From the
study, we suggested that xanthorrhizol may be able to dis-
rupt the cell plasma membrane as the late apoptotic event
was happened in a huge magnitude during a short expo-
sure time according to the flow cytometry analysis [3]. The
ability of an antiproliferative agent to disrupt the cell
plasma membrane was reported to have involved in the
cell protein membrane redox homeostasis and thus, facil-
itates the induction of apoptosis event [8]. Most recently,
curcumin was discovered to have membrane-thinning
effect and it also weaken the elasticity moduli of 1,2-dio-
leoyl-sn-glycero-3-phosphocoline (DOPC) bilayer [9]. It
is believed that enhanced cytotoxicity of anticancer drugs
could result from changes in the biophysical properties
and functions of tumor cell membranes induced by the
co-substance as suggested in other reports [10-12]. Mean-
while, in a study on antibacterial properties of xanthor-
rhizol, researchers have suggested the hydrophobic chain
of xanthorrhizol structure can penetrate and breakdown
the dental plaque biofilm, resulting the death of the
microorganism [13,14].
Interestingly, curcumin was reported to possess inhibitory
effect on the generation of reactive oxygen spesies (ROS)
and the inactivation of c-Jun NH2-terminal kinase (JNK)
pathway, which has been associated with chemotherapy-
mediated induction of apoptosis in tumor cells [15,16].
This was further proven in a study where curcumin was
tested to be able to compromise the proapoptotic activity
of camptothecin, alkylating agents and anthracyclines.
Besides, it decreased the camptothecin- and mechlo-
rethamine-induced mitochondrial cytochrome c  release
and lowering the effectiveness antitumor activity of cyclo-
phosphamide [17]. In some other studies, curcumin
instead showed synergistic growth inhibition and stimu-
late apoptosis on some cancer cells when combined with
chemotherapeutic drugs such as bortezomib and 5-fluor-
ouracil [18,19]. Therefore, the combined effect of the sub-
stances is more likely depends on the drug-drug
interaction. Xanthorrhizol also have the ability to attenu-
ate the activation of JNK in cisplatin-induced hepatoxcity
in mice [20]. Although both curcumin and xanthorrhizol
inactivated JNK pathway in some studies but apoptotic
cell death still likely to occur as curcumin and xanthor-
rhizol were tested to have alternative pathway in inducing
apoptotic cell death such as the p53-dependent pathway
[2,3,21] and mitochondrial-dependent pathway [4,22].
Taken together the ability of both curcumin and xanthor-
rhizol to disrupt the membrane fluidity and inducing
apoptotic cell death, we considered the possibility that
combined xanthorrhizol-curcumin might synergistically
inhibit the growth of cancer cells via apoptosis induction.
In the present study, the combined effect of xanthorrhizol
and curcumin was tested on highly invasive human breast
cancer cells, MDA-MB-231. This cell line is a good candi-
date for the study of invasive cancer in vitro. The MDA-MB-
231 cell line has lost its normal breast cell phenotype. The
MDA-MB-231 cell line expresses mutant tumor suppres-
sor gene, p53 and invasion factors such as MMP-1, MMP-
2, MMP-9 and vimentin but they do not expressed factors
such as E-cadherin or steroid receptors such as estrogens
and progesterone as compared to the other breast cancer
cell lines [23-25]. Furthermore, the MDA-MB-231 cell line
achieves high tumorigenicity in nu/SCID mice and exhib-
its invasive properties in vitro [26]. Therefore, the altered
phenotype in MDA-MB-231 cell line is associated with
tumor progression, metastases formation and resistance
to programmed cell death [27,28]. Hence, any antiprolif-
erative agent that can halt their proliferation is definitely
beneficial for the prevention and treatment of invasive
cancer.
In order to determine the best combination of xanthorri-
zol with curcumin, a fixed ratio concentration treatment
and different schedules of administration of the test
agents were compared to elucidate whether there was
schedule dependency. Both xanthorrhizol and curcumin
cytotoxicity on MDA-MB-231 cells were determined ear-
lier (data not shown). The interactions between xanthor-
rhizol and curcumin were evaluated for synergism,
additivity, or antagonism using both isobologram and
combination index method as preclinical screening test.
To investigate the mode of cell death induced by the com-
bined effect of xanthorrhizol and curcumin, we examined
whether apoptosis or necrosis cell death was involved.
Results
Xanthorrhizol was isolated from curcuma xanthorrhizza
Hydrodistillation of the freshly chopped rhizome of Cur-
cuma xanthorrhizza Roxb. yielded 0.44% of essential oil.
GC-MS results showed that xanthorrhizol is the major
chemical constituent in the essential oil as it makes up
nearly 46.3% of the total component (Figure 1A). Com-
pound 1 was obtained as light brownish oil and was given
name as xanthorrhizol. TLC profile of 1 presented the Rf
value of 0.27 using 5% diethyl ether in petroleum ether
(Figure 1B, 1C). Meanwhile, TIC profile showed an inte-
grated single peak of 1  with 100% peak area (CAS#
30199-26-9, Figure 1D). Its molecular formula was
obtained from high resolution mass spectrum which
showed [M+] ion at m/z 218.3210 corresponding to the
formula C15H22O; calc 218.3404 (Figure 2). In 1H NMRCancer Cell International 2009, 9:1 http://www.cancerci.com/content/9/1/1
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The extraction and isolation of xanthorrhizol from its crude essential oil Figure 1
The extraction and isolation of xanthorrhizol from its crude essential oil. The designated peak (xanthorrhizol) is the 
most abundance component, which accounted for 46.3% of the total component in the extracted essential oil of C. xanthor-
rhizza (A). Xanthorrhizol was detected via chromogenic reagent spray (0.5% vanillin/sulfuric acid) and UV (254 nm) visualiza-
tion in TLC profile as compare to the authentic reference substance (B and C). Final isolation process produced compound 1 
at 100% abundance (D) and the NMR spectral identified the compound 1 as xanthorrhizol (E).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
 
 
 
A 
Xanthorrhizol  
Rt = 29.27 min 
D 
E 
D 
Xanthorrhizol (Compound 1) 
Rt = 29.28 min 
E 
Xanthorrhizol  Cancer Cell International 2009, 9:1 http://www.cancerci.com/content/9/1/1
Page 4 of 12
(page number not for citation purposes)
Simultaneous treatment of xanthorrhizol and curcumin alters the mitochondrial transmembrane potential and induces apopto- sis in MDA-MB-231 cells Figure 2
Simultaneous treatment of xanthorrhizol and curcumin alters the mitochondrial transmembrane potential 
and induces apoptosis in MDA-MB-231 cells. MitoCapture™ dye was found localized and fluoresces red (arrow) in the 
mitochondrial of untreated cells. Number of cells fluoresces red was decreasing in line with the increasing dose of treatment, 
suggesting the disruption of the mitochondrial transmembrane potential (A). Phase contrast fluorescence images show that 
untreated cells were stained homogenously and no fluorescence was observed. In contrary, cell shrinkage was observed in the 
treated cells and fluorescence (arrow) was clearly detected in the nuclear region, indicating apoptotic morphology (B). X – 
xanthorrhizol. XC – combination of xanthorrhizol and curcumin. TAM – Tamoxifen (positive control).
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analysis, the presence of phenyl group was evident from
signals at δ(ppm) 6.63 (s, 1H), 6.71 (dd, 1H, J = 7.5, 1.8,
1.5 Hz) and 7.05 (d, 1H, J = 7.8 Hz) in the 1H NMR spec-
trum (Figure 1E).
Compound  1  (xanthorrhizol): Light brownish oil;
C15H22O; High MS m/z: M+ 218.3210 calc. 218.3404 for
C15H22O; Low MS m/z (%): 218(42), 48 (28), 136 (100),
121 (57), 135 (54); 1H NMR (300 MHz, CDCl3): δ 1.22
(d, 3H, J = 6.9 Hz, -CH3-6), 1.54–1.63 (m, 2H, -CH2-4),
1.70 (s, 6H, -C(CH3)2-1), 1.87–1.94 (m, 2H, -CH2-3),
2.24 (s. 3H, -CH3-10), 2.57–2.69 (m, 1, -CH-5), 5.08–
5.14 (m, 1H, -CH = C-2), 6.63 (s, 1H, Ph), 6.71 (dd, 1H,
J = 7.5, 1.8, 1.5 Hz, Ph), 7.05 (d, 1H, J = 7.8 Hz, Ph)
Synergistic effect of simultaneous treatment of 
xanthorrhizol and curcumin on MDA-MB-231 cells
Simultaneous treatment of fixed combination ratio with
an increasing fraction of curcumin has showed a synergis-
tic cytotoxic effect in MDA-MB-231 cells as revealed by the
isobologram and combination indexes method (Figure
3A, 3B). Synergistic activity was commenced from the
combination xanthorrhizol-curcumin 3:7 to 1:9. These
data reflects the vital involvement of curcumin in the sen-
sitiviy of MDA-MB-231 cells towards the test agents.
Cytotoxicity of sequential treatment of xanthorrhizol-
curcumin (X-C) and curcumin-xanthorrhizol (C-X) on 
MDA-MB-231 cells
We had conducted two types of sequential treatments
where xanthorrhizol or curcumin was used to treat the
MDA-MB-231 cells for 24 hours, followed by the removal
of total medium and replenished again with curcumin- or
xanthorrhizol-added medium at a fixed combination
ratio as in the simultaneous treatment for further 24
hours. The first treatment (X-C) showed antagonism at
lower fraction of xanthorrhizol but approaching additiv-
ity when the xanthorrhizol was at higher fraction (Figure
3C, D). In contrary, the latter treatment (C-X) resulted in
synergistic effect at higher fraction of curcumin and this
trend was quite similar with cells that are treated simulta-
neously with xanthorrhizol and curcumin (Figure 3E, F).
Results from both sequential treatments imply the cyto-
toxicity of the combined treatment of xanthorrhizol and
curcumin was schedule-dependent and curcumin may
plays a major role in enhancing the cytotoxicity of xanth-
orrhizol in the MDA-MB-231 cells. Hence, simultaneous
treatment was suggested as the better treatment route as
compared to both the sequential treatments.
Disruption of mitochondrial membrane potential of MDA-
MB-231 cells after simultaneous treatment with 
xanthorrhizol-curcumin
The cationic dye MitoCapture™ was able to enter the cell
cytoplasm, accumulate and aggregate in mitochondria,
thus producing a bright red fluorescence. This red fluores-
cence was easily distinguished in untreated MDA-MB-231
cells. Remarkably, increasing doses of xanthorrhizol-cur-
cumin simultaneous treatment resulted in significant
reduction of this red fluorescence. On the other hand,
there were an increasing number of treated cells which
only fluoresces green. This is due to the inability of Mito-
Capture™ to accumulate in mitochondria as the mito-
chondrial transmembrane potential alters during
apoptosis events. They remain as green monomers in the
cytoplasm of apoptotic cells. A similar trend of fluores-
cence was also seen in MDA-MB-231 cells when treated
with 15 μg/ml of xanthorrhizol (X) and 5 μg/ml and 10
μg/ml tamoxifen (TAM) respectively (Figure 2A).
Hoechst 33258 nuclear staining
The Hoechst 33258 dye was able to diffuse through intact
membranes of MDA-MB-231 cells and stain their DNA. As
the concentration of combined xanthorrhizol-curcumin
increased, single intense fluorescence and multiple strong
fluorescence signals were produced in the cell nuclei (Fig-
ure. 2B). The control culture (untreated MDA-MB-231)
was uniformly stained with no substantial fluorescence
signal, whereas the treated cells showed clear apoptotic
morphology. According to the fluorescence and phase
contrast images, shrinkage of cells and plasma membrane
convolution were all observed in the treated cells. Similar
apoptotic morphology was also observed in the MDA-
MB-231 cells treated with 15 μg/ml xanthorrhizol (X). The
number of apoptotic cells was determined and expressed
as percentage of apoptotic index. Simultaneous treatment
with combined xanthorrhizol-curcumin resulted in a dose
dependent increase in apoptotic cells (Figure 4).
Treatment with xanthorrhizol-curcumin induced the inter-
nucleosomal excision in MDA-MB-231 cells
DNA fragmentation is a biochemical hallmark of apop-
totic cell death. From the agarose gel, DNA samples from
the treated MDA-MB-231 cells exhibit intact genomic
DNA (gDNA) and clear DNA ladders during treatment at
higher doses (Figure 5). Treatments at lower doses
showed only intact gDNA and do not marked any DNA
laddering or even smearing effect. When the multiple
bands were analyzed, they showed ~180 bp inter-nucleo-
somal excision, thus confirming apoptosis but not necro-
sis had taken place. Lane T and C consist of DNA sample
from taxol-treated MDA-MB-231 cells and actinomycin-
treated HL 60 cells respectively as positive control. The
same pattern of DNA laddering was observed.
Discussion
Plants have been utilized as medicines for thousands of
years. These medicines initially took the form of crude
drugs such as powders, tea and other formulations. The
use of medicinal plant was then developed into anticancerCancer Cell International 2009, 9:1 http://www.cancerci.com/content/9/1/1
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Isobolograms and combination indexes at 50% effect level of simultaneous and sequential exposure of MDA-MB-231 cells to  xanthorrhizol and curcumin Figure 3
Isobolograms and combination indexes at 50% effect level of simultaneous and sequential exposure of MDA-
MB-231 cells to xanthorrhizol and curcumin. The dashed line (CI = 1) indicates the alignment of theoretical values of an 
additive interaction between two substances. Values above the dashed line indicate an antagonistic interaction, and values 
below indicate synergism interaction. Simultaneous treatment involved concurrent 48 h exposure of MDA-MB-231 cells to 
xanthorrhizol and curcumin (A and B) whereas sequential treatment was 24 h exposure to xanthorrhizol followed by curcumin 
for subsequent 24 h (C and D) or vice versa (E and F). Simultaneous treatment inhibits the growth of MDA-MB-231 cells more 
synergistically as compared to the sequential treatment. Results are representative of three independent experiments con-
ducted.
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drugs. This involves the isolation and characterization of
pharmacological active compounds. More recently, drug
discovery techniques have been moved on to the use of
combined active compounds where they are believed to
be more active as compared to the single agent itself.
Therefore, the efficacy of treatment would increases and
the possibility of toxic effect may be lowered due to the
extremely low usage of drug [29]. Both xanthorrhizol and
curcumin have been reported to have a wide spectrum of
pharmacological activities [20,30-35]. They also involved
in some anticancer studies [2-7,36,37]. Moreover, curcu-
min is currently involved in early phase of clinical trial as
potential chemopreventive agent [38-42]. Hence, it is
rational to investigate the combined effect of xanthor-
rhizol and curcumin as a new antiproliferative agent for
breast cancer cells.
In the present study, the biologically active xanthorrhizol
(1) was isolated as light brownish essential oil. Analysis of
1H-NMR spectrum of 1, revealed that it has a characteristic
sesquiterpenoid skeleton, closely related to α-curcumene,
a 1-(1,5-dimethyl-hex-4-enyl)-4-methyl-benzene deriva-
tive with a bisabolane-type sesquiterpenoid [36,43]. The
mass fragmentation of 1 was very close to that reported by
Itokawa and colleagues [36]. The methyl proton attached
to the aromatic functional group, next to the hydroxyl
group gives resonance at δ 2.238 ppm (s. 3H, -CH3-10).
The existence of phenyl group in 1 was suggested by the
proton resonance at δ 6.630 (s, 1H, Ph), 6.712 (dd, 1H, J
= 7.5, 1.8, 1.5 Hz, Ph), 7.049 (d, 1H, J = 7.8 Hz, Ph) in the
1H NMR spectrum. The results consigned are in agreement
with a bisabolane sesquiterpeoid skleton in 1. Compari-
son of the spectroscopic properties with those related
Apoptosis level after treatment of xanthorrhizol and simultaneous treatment of xanthorrhizol-curcumin as determined from  Hoechst 33258 staining Figure 4
Apoptosis level after treatment of xanthorrhizol and simultaneous treatment of xanthorrhizol-curcumin as 
determined from Hoechst 33258 staining. The treatment for 24 h induced exponential apoptotic cell death in a dose 
dependent manner as compare to untreated control. Results are presented as means ± SD of 3 independent experiments. *p < 
0.05, **p < 0.005 statistically significant values relative to untreated control.
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compound previously isolated supported the structural
assignments [43].
From the isobologram and combination index analysis,
simultaneous treatment of xanthorrhizol and curcumin
made the best treatment as compare to the sequential
treatments. Both simultaneous and sequential treatment
of xanthorrhizol and curcumin have highlighted that the
involvement of curcumin is vital in the growth inhibition
of MDA-MB-231. However, a study on drug and drug
interaction, pharmacognosy and other research need to be
conducted to confirm their intervention action.
Study on the mode of cell death induced by the simulta-
neous treatment of combined xanthorrhizol and curcu-
min was conducted in this study. Apoptosis is a
programmed cell death which is activated to expel dam-
aged cells, excessive numbers of cells and cells that are not
needed during the development and normal tissue home-
ostasis [44]. Failing of trigger apoptotic cell death may
lead to the development of neoplasia [45]. Therefore,
cytotoxicity effect via the induction of apoptosis was con-
sidered as criteria for the identification or screening for a
new cancer chemotherapy agent [46], and most chemo-
therapeutic drugs induce apoptosis in cancer cells [47].
The inability of MDA-MB-231 cells to undergo apoptosis
in response to anticancer stimuli has been highlighted in
recent study [48]. However, our investigations showed
that xanthorrhizol was able to induce apoptotic cell death
in the MDA-MB-231 cell line. The combination treatment
was tested to induce apoptosis cell death. There were few
hallmarks of apoptosis observed in our study. The depo-
larization of mitochondrial occurred in a dose dependent
manner and this suggest the release of cytochrome c from
the mitochondria intermembrane to the cytosol was being
facilitated. Cytochrome c is a vital protein in leading the
cancer cells to mitochondria-dependent apoptosis
through a channel of caspases activation [49-51]. How-
ever, the exact mechanism of the mitochondrial mem-
brane permeability and the distribution of cytochrome c
still remain to be elucidated. In our study, tamoxifen was
used as positive control as it has been reported to induce
apoptosis in MCF-7 and MDA-MB-231 breast cancer cells
via the mitochondrial pathway involving the release of
cytochrome c [52].
There was a marked increase of apoptotic index after treat-
ment with combined xanthorrhizol-curcumin. Immun-
ofluorescence images showed that the dying cells exhibit
ultrastructural and biochemical features that character-
ized apoptosis, as shown by the loss of cell viability, DNA
condensation, DNA fragmentation and cell shrinkage
[3,47,53]. Recently, xanthorrhizol treatment has been
reported to cause apoptotic cell death in MCF-7 [3], HeLa
[2], and HepG2 cancer cell lines as well [4]. Cell shrinkage
happens only in apoptotic cell death. Cells intracellular
concentration of monovalen ions (K+ and Na+) was able
to inhibit activation of cell death cascade. Therefore, the
ions will be expelled out during apoptotic event and this
will cause the cell to shrink. As compare to necrosis, ionic
homeostasis occurs due to the drastically decrease of
energy level. This event will cause the increase of cell vol-
ume and subsequently, swelling and total cell lysis will be
observed [54,55].
DNA laddering is a definitive indication of whether cells
are undergoing apoptosis or necrosis [56]. Inter-nucleo-
somal excision at ~180 bp interval was observed after the
treatment with xanthorrhizol-curcumin. This DNA frag-
mentation event occurred in-line with the increased level
of apoptotic index. It also indicates the point of no return
for a dying cell as cleavage of gDNA by endogenous endo-
nucleases during apoptosis is an irreversible event that
commits cell to die [57]. Hence, the possibility of cells
Simultaneous treatment of xanthorrhizol and curcumin  induces DNA fragmentation in MDA-MB-231 cells Figure 5
Simultaneous treatment of xanthorrhizol and curcu-
min induces DNA fragmentation in MDA-MB-231 
cells. At lower doses of treatment, only high molecular 
weight intact DNA was observed whereas small fragments of 
DNA were highlighted at higher doses of treatment. The 
fragments of DNA have interval molecular weight of ~180 
bp, suggesting an apoptotic event. Results are representative 
of three independent experiments carried out. M – Marker. 
0, 5, 10, 15, 20, 25 μg/ml – DNA samples from xanthor-
rhizol-curcumin (XC)-treated cells at different concentra-
tion. T – DNA sample from taxol-treated MDA-MB-231 cells 
(positive control). C – DNA sample from actinomycin-
treated HL 60 cells (positive control).
2000 bp
1500 bp
1000 bp
750 bp
500 bp
300 bp
150 bp
50 bp
~ 1125 bp
~ 912 bp
~ 706 bp
~ 518 bp
~ 318 bp
~ 151 bp
M 0 5 10 15 20 T 25 C
2000 bp
1500 bp
1000 bp
750 bp
500 bp
300 bp
150 bp
50 bp
~ 1125 bp
~ 912 bp
~ 706 bp
~ 518 bp
~ 318 bp
~ 151 bp
M 0 5 10 15 20 T 25 CCancer Cell International 2009, 9:1 http://www.cancerci.com/content/9/1/1
Page 9 of 12
(page number not for citation purposes)
regain the proliferative activity is very low and thus, simul-
taneous treatment of xanthorrhizol-curcumin has advan-
tage to become a new combination treatment for MDA-
MB-231 human breast cancer cells.
Conclusion
The experimental evidence from this study suggests that
simultaneous treatment of xanthorrhizol and curcumin
exhibits synergistic effect towards human breast carci-
noma cells MDA-MB-231 whereas sequential treatment
with xanthorrhizol and curcumin or vice versa did not
showed greater advantages as compare to the simultane-
ous treatment. The combination treatment induced apop-
totic cell death as the experimental evidence from this
study revealed that alteration of membrane potential,
DNA condensation, cell shrinkage and DNA fragmenta-
tion were observed after the treatment. Taken together
with the antiproliferative activity of xanthorrhizol and
curcumin, antimetastatic activity of xanthorrhizol, organ
protective effect of xanthorrhizol, we believe combined
treatment of xanthorrhizol-curcumin could be a potential
antiproliferative agent for invasive breast cancer cells.
However, in-depth studies especially in the molecular
mechanism of apoptotic cell death need to be conducted
to assure its efficacy.
Methods
Extraction and isolation of xanthorrhizol
Fresh rhizomes of C. xanthorrhizza Roxb. were chopped
and essential oils were obtained by hydrodistillation in a
modified Clevenger-type apparatus. Distilates were then
extracted 3 times with diethyl ether. The pooled organic
phases were dried and subjected to two rounds of silica gel
vacuum column chromatography (VCC) separation
(Merck silica gel 60, 0.040–0.063 mm; and Merck silica
gel 60, 0.063–0.200 mm respectively). The columns were
eluted with petroleum-ether with gradual increase ratio of
diethyl ether. The existence of xanthorrhizol in each frac-
tion was pre-identified using thin layer chromatography
(TLC) and gas chromatography-mass spectrometry (GC-
MS) by comparing the retention factor (Rf) in TLC profile
and the total ion chromatogram (TIC)/Mass spectra in
GC-MS profile respectively with those of authentic refer-
ence substance (Alexis Biochemicals, Switzerland). Frac-
tions were subjected to GC-MS analysis on an Agilent
system with a model 6890 gas chromatography, a model
5073 Mass Selective detector (MSD) and an Agilent
Chemstation data system. The following GC oven temper-
ature program was used: 40°C initial temperature; held
for 2 min; increased at 5°c/min to 230°C with split (50:1)
injection.
From our previous study, xanthorrhizol is not able to be
separated by normal CC using mixture of solvents with
different polarity as other compounds always appeared
together as co-eluents. In an effort to purify xanthorrhizol
from the final fraction from VCC, subsequent reaction
steps (Scheme 1 and Scheme 2) were conducted to facili-
tate the isolation and purification. Xanthorrhizol was
reported as a potential chiral starting material for the syn-
thesis of other sesquiterpenoids [43]. As a result, we
started the process of acetylation towards fractions that
comprise compound 1 and other co-eluents to produce a
lower polarity compound 2 namely, acetyl-xanthorrhizol
(Scheme 1).
Scheme 1: (Acetylation process)
This particular fraction which consists of compound 2
and other components was subjected to open CC to sepa-
rate compound 2 and other compounds. Compound 2
was easily separated from other compounds in this step as
its polarity was increased after the acetylation process. Fol-
lowing fractions which contain only 2 were then pooled
and undergone hydrolysis to produce back xanthorrhizol
(1), as showed in scheme 2. Subsequent partition was
then able to separate 1  into organic phases in EtOAc.
Finally, evaporation of the organic solvent yielded 1 as a
light brownish oil with 71% yield.
Scheme 2: (Hydrolysis process)
Identification of 1 was carried out by comparing its GC
mass spectral to the authentic reference substance (Alexis
Biochemicals, Switzerland), referring to the NIST98 data-
base/Chemstation data system (National Institute of
Standards and Technology, Gaithersburg, MD, USA). Sub-
sequent identification was conducted by using 1H-NMR
analysis. NMR spectral (300 MHz) of 1 was recorded on a
Bruker Avance 300 Spectrometer using CDCl3 as solvent.
Chemical shifts are reported in ppm with reference to
residual solvent [CHCl3 (7.26)].
Cell culture
MDA-MB-231 human breast cancer cell line was obtained
from the American Type Culture Collection (ATCC, Man-
assas, VA, USA). They are maintained in Dulbecco's mod-
ified Eagle's medium (DMEM; Invitrogen Co., Carlsbad,
OAc OH
N
O O
O
, Et2O, RT, 8h
pyridine
acetic anhydride
1  2 
1.5 eq 
2 eq 
1 2
3 eq 
OH OAc
MeOH/H2O, RT, 8h
K2CO3
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CA, USA) supplemented with 5% heat-inactivated fetal
calf serum (Invitrogen Co.), 100 U/ml penicillin and 100
mg/ml streptomycin (Flowlab, Sdyney, Australia) in a
humidified atmosphere of 5% CO2 in air at 37°C. Cells
were kept in the logarithmic growth phase by routine pas-
sage every 2–3 days using 0.025% trypsin-EDTA treat-
ment.
Cell growth assay
The antiproliferative activity of fixed ratio combination of
xanthorrhizol and curcumin (from 1:9 to 9:1) towards
MDA-MB-231 human breast cancer cell line was evaluated
by using the sulforhodamine B (SRB) method, as previ-
ously described [58,59]. Cells were seeded 24 hours prior
to treatment in a 96-well plate at plating densities 15, 000
cells/well in order to obtain semi-confluent cultures. One
plate from the cell line was fixed in situ with TCA (Sigma
Chemical Co.), to represent a measurement of the cell
population for each cell line at the time of drug addition
(Tz). Combination solutions were dissolved in DMSO
(Sigma Chemical Co.) and followed by a 2× serial dilu-
tion for 6 points ranged from 40 μg/ml to 1.25 μg/ml. The
final concentration of DMSO used in the corresponding
wells did not exceed 1% (v/v), which affect cell viability.
Following drug addition, the plates were incubated for an
additional 48 hours.
At the end of incubation, cells were fixed in situ with 50
μl of cold 50% (w/v) TCA and incubated for 1 hour at
4°C. The plates were then washed with tap water and air
dried. SRB (Sigma Chemical Co.) solution (100 μl) at
0.4% (w/v) in 1% acetic acid was added to the corre-
sponding wells and further incubated for 10 minutes at
room temperature. After staining, unbound dye was
washed out by 1% acetic acid and the bound stain was
subsequently solubilised with 10 mM trizma base (Sigma
Chemical Co.). The absorbance at 505 nm was read on a
spectrophotometric plate reader.
Dose-response curves were constructed to obtain the
response parameter which was the GI50. Percentage
growth is calculated as: [(Ti - Tz)/(C - Tz)] × 100 where (Tz)
is time zero, (C) is control growth and (Ti) is test growth
in the presence of drug at the six concentration levels. The
GI50 value (growth inhibitory activity) corresponds to the
concentration of test agents causing 50% decrease in net
cell growth which was calculated from [(Ti - Tz)/(C - Tz)] ×
100 = 50. All data were derived from 3 independent exper-
iments.
Isobologram and combination-index analysis
Drug synergy was determined by the isobologram analysis
and combination-index (CI) methods, as described else-
where [60,61]. Isobologram analysis was used to deter-
mine the effects of combinations of drugs on MDA-MB-
231 cells whereas the CI method is a mathematical and
quantitative representation of two-drug pharmacologic
interaction. Using data from the growth inhibition assay,
classic isobologram was constructed and CI values were
then calculated by using the following formula: CI = (d1/
Dx1) + (d2/Dx2), where Dx is the dose of one drug alone
required to produce a 50% growth inhibition, and d1 and
d2 are the doses of xanthorrhizol and curcumin respec-
tively, in combination that produce the same effect (50%
growth inhibition). A CI of > 1 implies antagonism, = 1 is
additivity, and < 1 is synergy.
Analysis of alteration of mitochondrial membrane 
potential
Changes in the mitochondrial membrane potential of
treated MDA-MB-231 cells were examined using a fluores-
cent microscope (Imaging Source Europe GmbH) and
MitoCapture™ Mitochondrial Apoptosis Detection Kit
(BioVision Research, Moutain View, CA, USA), according
to the manufacturer's instructions. Briefly, treated and
untreated cells were washed with PBS. One μl of MitoCap-
ture dye was diluted to 1 ml pre-warmed incubation
buffer immediately prior to use. The cells were then incu-
bated in 500 μl of the diluted MitoCapture solution at
37°C for 20 minutes in a CO2 incubator before being
observed under a fluorescence microscope using a band-
pass filter.
Hoechst 33258 nuclear staining assay
Nuclear staining with Hoechst 33258 (Sigma Chemical
Co.) was performed as described elsewhere [3,62]. Briefly,
treated and untreated cells were washed with phosphate
buffered saline (PBS) followed by incubation in 10 μM
Hoechst 33258 solution at room temperature for 20 min.
At the end of incubation, cells were washed extensively
with PBS. Nuclear morphology was then examined under
a fluorescence microscope (Imaging Source Europe
GmbH, Bremen, Germany). To quantify the apoptotic
index, the percentage of single and multi intense-fluo-
resced cells (apoptotic morphology) were calculated from
five random microscopic fields at ×40 magnification.
DNA fragmentation assay
DNA fragmentation assay is a definitive assay to confirm
apoptotic cell death has taken place in the cultures. DNA
fragmentation assay was conducted using the Suicide
Track™ DNA Ladder Isolation Kit (Calbiochem), accord-
ing to manufacturer's instructions. Briefly, MDA-MB-231
cells were cultured in a T-25 flask and treated with com-
bined solution of xanthorrhizol-curcumin for 24 hours.
Floating and and trypsinized-adherent of treated and
untreated cells were collected by centrifuging at 900 × g
for 5 min. Cell pellets were then resuspended in 250 μl of
extraction buffer following incubation on 4°C for 30 min.
The suspensions were then centrifuged at 16, 000 × g forCancer Cell International 2009, 9:1 http://www.cancerci.com/content/9/1/1
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5 min at room temperature. The resulting supernatant
were transferred to a clean tube, followed by the addition
of 10 μl of RNase A solution and incubated at 37°C for 1
h. DNA isolation buffer was added and further incubated
at 50°C for overnight. During the DNA precipitation step,
2 μl of Pellet Paint® Co-precipitant was added to the sus-
pension together with 30 μl of 3 M sodium acetate and
311 μl of 2-propanol. Samples were mixed by inversion
and then centrifuged at 16, 000 × g for 5 min. The result-
ing pellets were washed with 70% and 100% ethanol. The
DNA samples were then air-dried and resuspended in 50
μl of resuspension buffer (10 mM Tris, 1 mM EDTA).
Finally, DNA samples were separated in 2% agarose gel in
1× TAE. Positive control was supplied by Calbiochem
which consist of 1 × 106 HL60 cells treated with 0.5 mg/
ml Actinomycin D for 19 h.
Statistical analysis
All data were expressed as mean ± standard deviation. The
statistical differences were analyzed using one-way
ANOVA followed by a Tukey Honestly Significantly Dif-
ferent (HSD) test. Values of p < 0.05 were considered sig-
nificant.
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